The intrarenal renin-angiotensin system (RAS) plays an important role in the progression of diabetic nephropathy. We have previously reported that mice overexpressing angiotensinogen in renal proximal tubular cells (RPTC) develop hypertension, albuminuria, and renal injury. Here, we investigated whether activation of the intrarenal RAS contributes to apoptosis of RPTC in diabetes. Induction of diabetes with streptozotocin in these transgenic mice led to significant increases in BP, albuminuria, RPTC apoptosis, and proapoptotic gene expression compared with diabetic nontransgenic littermates. Insulin and/or RAS blockers markedly attenuated these changes. Hydralazine prevented hypertension but not albuminuria, RPTC apoptosis, or proapoptotic gene expression. In vitro, high-glucose medium significantly increased apoptosis and caspase-3 activity in rat immortalized RPTC overexpressing angiotensinogen compared with control cells, and these changes were prevented by insulin and/or RAS blockers. In conclusion, intrarenal RAS activation and high glucose may act in concert to increase tubular apoptosis in diabetes, independent of systemic hypertension. Diabetic nephropathy (DN) is the leading cause of all ESRD in North America, accounting for 45% to 50% of all cases. 1,2 Intensive insulin therapy and chronic treatment with renin-angiotensin system (RAS) blockers are effective in retarding DN progression but do not provide a cure. [3] [4] [5] The local intrarenal RAS is well accepted. 6,7 Renal proximal tubular cells (RPTC) express all components of the RAS. 8 -10 Angiotensin II (Ang II) levels and RAS genes are elevated in the kidneys of diabetic rats and humans, 11-13 implying an important role for the intrarenal RAS in DN progression.
Diabetic nephropathy (DN) is the leading cause of all ESRD in North America, accounting for 45% to 50% of all cases. 1, 2 Intensive insulin therapy and chronic treatment with renin-angiotensin system (RAS) blockers are effective in retarding DN progression but do not provide a cure. [3] [4] [5] The local intrarenal RAS is well accepted. 6, 7 Renal proximal tubular cells (RPTC) express all components of the RAS. 8 -10 Angiotensin II (Ang II) levels and RAS genes are elevated in the kidneys of diabetic rats and humans, [11] [12] [13] implying an important role for the intrarenal RAS in DN progression.
Glomerular changes in DN first consist of hypertrophy and, later, thickening of the glomerular basement membrane, followed by expansion of the mesangial matrix and glomerulosclerosis. 14 -16 However, the gradual decline of renal function in later stages of DN is invariably associated with tubular atrophy and interstitial fibrosis, hallmarks of ESRD. 17, 18 In fact, tubular atrophy and interstitial fibrosis are closely associated with loss of renal function and appear to be better predictors of renal disease progression than glomerular pathology. [15] [16] [17] [18] Tubular atrophy in DN is incompletely understood, although apoptosis is a candidate mechanism. Indeed, apoptosis has been detected in RPTC of diabetic mouse, rat, and human kidneys. 19 -24 Our previous study documented that transgenic (Tg) mice overexpressing rat angiotensinogen (rAgt) cDNA in RPTC are prone to develop hypertension, albuminuria, and renal injury. 25 The present study investigated whether intrarenal RAS activation could act in concert with high glucose to enhance RPTC apoptosis independent of systemic hypertension and whether treatment with insulin, RAS blockers, or a combination of both could reverse these events.
RESULTS

Tissue-specific Expression of the rAgt Transgene in Tg Mice
The rAgt-HA transgene was expressed only in the kidneys (Figure 1A) and RPT of adult male Tg mice ( Figure 1B ) but not in other tissues and RPT of non-Tg mice. Immunostaining confirmed the increased expression of Agt protein in RPTC of Tg mice ( Figure 1C ). In subsequent experiments, testosterone pellets were not used, because the endogenous testosterone was sufficient to induce rAgt-HA transgene in adult male Tg mice.
Renal Hypertrophy and Albuminuria in Diabetic rAgt-Tg Mice
As expected, STZ administration resulted in elevated blood glucose levels in both non-Tg and Tg mice ( Figure 2A ) and increased the kidney/body weight and urinary albumin/creatinine ratio (Figure 2 , B and C). Insulin normalized these parameters in both diabetic non-Tg and Tg mice. Treatment with RAS blockers also attenuated the kidney/body weight ratio and the urinary albumin/creatinine ratio without affecting blood glucose level. Treatment with insulin plus RAS blockers completely reversed all changes observed in diabetic Tg mice (Figure 2 , B and C). Of note, the urinary albumin/creatinine ratio in Tg mice was significantly higher than in non-Tg mice (Figure 2C ).
Hypertension in Tg Mice
We detected slight elevations in mean systolic BP in male Tg mice starting at week 11; however, these increases became statistically significant only at week 12 and thereafter ( Figure 3A ). Hydralazine treatment (commenced on week 14) reduced BP of Tg mice to that of non-Tg mice after 1 wk of treatment ( Figure 3A ). STZ-induced diabetes did not evoke further increases in BP in non-Tg and Tg mice, and insulin treatment did not reduce BP ( Figure 3B ). In contrast, treatment with RAS blockers alone or in combination with insulin significantly decreased BP in both diabetic non-Tg and Tg mice ( Figure 3B ).
Morphologic Studies
As expected, diabetic non-Tg mice developed glomerular and RPTC hypertrophy ( Figure 4A , a and b) and exhibited a large number of detached cells and cell debris in the tubular lumen and loss of the brush border in RPTC in diabetic kidneys, indicating RPTC damage. Treatment with insulin ( Figure 4A , c) or RAS blockers ( Figure 4A, d ) attenuated the glomerular hypertrophy and tubular damage in diabetic non-Tg mice.
Unlike non-Tg mice, renal structural damage was evident in nondiabetic Tg mice. Histologic findings included vacuole degeneration in RPTC and accumulation of cell debris in the tubular lumen ( Figure 4A , e). Kidneys of diabetic Tg mice showed even more severe morphologic changes, including marked tubular luminal dilation, cell debris accumulation inside tubules and loss of brush border in RPTC ( Figure 4A, f) . Some RPTC even became flattened. Treatment with insulin ( Figure 4A, g ) or RAS blockers ( Figure 4A , h) markedly attenuated, whereas combination of insulin and RAS blockers completely reversed, these abnormalities ( Figure 4A, i) .
Glomerular volume, RPTC volume, and tubular luminal area were significantly increased in diabetic non-Tg and Tg mice compared with nondiabetic littermates (Figure 4 , B, C, and D). Once again, treatment with insulin or RAS blockers alone effectively attenuated, whereas the combination treatment fully reversed, these changes. It should be noted that RPTC volume ( Figure 4C ) but not glomerular volume ( Figure  4B ) was significantly higher in Tg mice than in non-Tg mice. In contrast, tubular luminal area was significantly lower in Tg mice than in non-Tg mice ( Figure 4D ). Similar pattern for cell debris quantification was observed in these studies (data not shown). Likewise, immunohistochemistry showed increased staining for active caspase-3 and Bax in RPTC of diabetic non-Tg Figure 2 . Blood glucose, kidney/body weight ratio, and urinary albumin/creatinine ratio in male non-Tg and Tg mice after 4 wk of STZ-induced diabetes with or without treatment with insulin or RAS blockers. (A) Blood glucose. Blood glucose was measured in the morning without fasting at the end of the study. (B) Kidneyto-body-weight ratio. The kidney-to-body-weight ratio was measured as the weight of two kidneys per body weight. (C) Urinary albumin (g/ml)/creatinine (mg/dl) ratio. All data are expressed as means Ϯ SD, n ϭ 8 (*P Ͻ 0.05, **P Ͻ 0.01; ***P Ͻ 0.005; NS). Non-Tg (empty bars) and Tg (solid bars) mice. Figure 6B ) and by Western blotting of active caspase-3 and Bax from isolated RPT ( Figure 6C and Figure 7C ). Taken together, these data demonstrate that rAgt overexpression further enhances RPTC apoptosis and proapoptotic gene expression in diabetic Tg mice. Hyperglycemia alone increased Bax mRNA (Figure 8, A) and decreased Bcl-xL mRNA expression ( Figure 8B ) in both non-Tg and Tg mouse RPT. Combined treatment with insulin and RAS blockers was more effective in reversing these changes than treatment with insulin or RAS blockers alone. These studies demonstrate that hyperglycemia and intrarenal RAS activation act in concert to alter the ratio of Bax and Bcl-xL mRNA expression, consistent with enhanced RPTC apoptosis.
Effect of Hydralazine in Tg Mice
Hydralazine treatment markedly reduced systemic BP in Tg mice without producing significant effects on blood glucose, the kidney/body weight ratio, and albuminuria ( Figure 9 ). Furthermore, hydralazine failed to affect RPTC apoptosis ( Figure  10 ), caspase-3 and Bax immunostaining, and Bax and Bcl-xl mRNA expression (Figure 11 ). These results indicate that albuminuria and RPTC apoptosis occur independently of systemic hypertension.
Agt Overexpression and High-Glucose-Enhanced Rat Immortalized RPTC Apoptosis In Vitro Culture of RPTC stably transfected with pRC/RSV or pRSV/ rAGT in high-glucose medium led to enhanced apoptosis and caspase-3 activity (Figure 12 ). Consistent with our in vivo observations, high-glucose-induced RPTC apoptosis and caspase-3 activity were attenuated in the presence of insulin or RAS blockers, with complete inhibition being achieved in the presence of both insulin and RAS blockers (Figure 12 ). Thus, RAS activation and high glucose can directly induce RPTC apoptosis. Figure 8 . RT-qPCR assays of Bax and Bcl-xL mRNA expression in RPT of non-Tg and Tg mice after 4 wk of STZ-induced diabetes with or without treatment with insulin or RAS blockers or insulin plus RAS blockers. Bax and ␤-actin or Bcl-xL and ␤-actin mRNA were run simultaneously in the same RT-qPCR assay. The CT (threshold cycle) value was measured to determine the starting copy number of target genes using the standard curve. Lower CT values indicate higher amounts of PCR products. Bax and Bcl-xL mRNA levels were normalized by corresponding ␤-actin mRNA levels. Bax and Bcl-xL mRNA levels in nondiabetic non-Tg were considered as 100%. All data are expressed as means Ϯ SD, n ϭ 8 (*P Ͻ 0.05, **P Ͻ 0.01; ***P Ͻ 0.005; NS). Non-Tg (empty bars) and Tg (solid bars) mice. 
DISCUSSION
The present observations indicate that renal rAgt overexpression and high blood glucose act in concert to induce albuminuria and RPTC apoptosis in diabetic Tg mice independent of systemic hypertension.
The transgene expression in our model is kidney-specific because strong rAgt-HA mRNA and Agt protein expression was observed in RPTC of Tg mice. Four weeks post-STZ, the mice exhibited high blood glucose levels, increased kidney to body weight ratio, and albuminuria, characteristics of STZinduced diabetes. 26, 27 Insulin treatment ameliorated these changes. Treatment with RAS blockers exerted similar beneficial actions, with the exception of blood glucose level, which remained high after RAS blockade. These findings suggest that renal changes can be attributed to the diabetic state per se rather than to a nephrotoxic effect of STZ.
Male Tg mice had significantly higher systolic BP than non-Tg littermates, and STZ-induced diabetes did not lead to significant additional increases in systolic BP. The effectiveness of RAS blockers in reducing BP in Tg mice implicates the involvement of intrarenal RAS activation in the development of hypertension.
Our data indicate the presence of apoptosis in RPTC and, to a lesser degree, in the distal tubule, with no obvious involvement of glomeruli in diabetic kidneys regardless of the transgene expression. Indeed, glomeruli of diabetic Tg and non-Tg animals did not show apoptotic morphology and stained negative for active caspase-3 and Bax. These observations are consistent with previous findings that diabetes induces apoptosis in RPT, but not in glomeruli of db/db mice and STZ-diabetic rats. 28, 29 Our results highlight an important role for intrarenal Agt gene expression in mediating tubular apoptosis in the diabetic mouse kidney. Indeed, the numbers of TUNEL-positive RPTC were significantly higher in Tg mice than in non-Tg mice and were effectively reduced after treatment with RAS blockers. Losartan reduced the number of apoptotic cells in kidneys of STZ-induced diabetic rats 21 and Ren-2 rats 22 and prevented Ang II-stimulated RPTC apoptosis 30 and glomerular cells in vitro. 31 Consistent with the findings in the TUNEL assay, RPT of diabetic non-Tg and Tg mice exhibited enhanced active caspase-3 and Bax expression. These changes were attenuated by treatment of mice with insulin or RAS blockers alone, with complete inhibition being achieved with insulin plus RAS blockers. Although active caspase-3 and Bax expression was undetectable in wild-type animals by immunostaining and Western blotting, both caspase 3 and Bax were highly expressed in Tg mice. Enhanced Bax expression occurred with concomitant down-regulation of the anti-apoptotic gene BclxL. Treatment with insulin or RAS blockers reversed the Bax/ Bcl-xL ratio that was further reduced by insulin plus RAS blockers. An increase in the Bax/Bcl-xL ratio would promote apoptosis and is a likely mechanism of how intrarenal RAS activation and high blood glucose enhanced tubular apoptosis in diabetes.
Next, we addressed whether intrarenal RAS-induced kidney injury was due to elevated systemic BP. Hydralazine treatment of Tg mice decreased hypertension; however, it failed to affect albuminuria, RPTC apoptosis, and proapoptotic gene expression. This study shows for the first time that intrarenal rAgt overexpression does lead to the development of hypertension, and albuminuria and RPTC apoptosis occur independently of systemic hypertension. Our in vitro findings that rAgt overexpression and high glucose can induce RPTC apoptosis further indicate a direct action on the kidney. Taken together, these data provide evidence that intrarenal RAS and high glucose could act in concert to induce tubular apoptosis in diabetes.
The precise molecular mechanism(s) by which intrarenal RAS and high glucose enhanced RPTC apoptosis in our Tg mouse model remain unclear. High glucose and Ang II are known to stimulate ROS, and ROS through activation of p38 MAPK 32 would stimulate p53 phosphorylation. 33 After translocation to the nucleus, the phosphorylated p53 would enhance Bax gene transcription. 34 Bax translocates to the mitochondria and binds the antiapoptotic proteins Bcl-2 and Bcl-xL and inhibits their protective actions on gate-keeping, ultimately leading to mitochondrial dysfunction and activation of caspase-3. Our data on increased Bax and caspase-3 expression combined with decreased Bcl-xL expression in RPT of diabetic Tg mice lend support to this notion.
The pathophysiological importance of RPTC apoptosis induced by rAgt overexpression remains to be elucidated. Because tubular cells undergo apoptosis in murine and human diabetic kidneys 19 -24 and the present study, we propose that RPTC apoptosis may be an initial mechanism leading to tubular atrophy that has been detected in the kidneys of diabetic patients. 35, 36 Taken together, our results suggest that activation of intrarenal RAS and high blood glucose act in concert to induce RPTC apoptosis independent of systemic hypertension and likely lead to tubular atrophy in diabetes. Our data also indicate that treatment with insulin plus RAS blockers could prevent tubular apoptosis and DN progression.
CONCISE METHODS
The pKAP2 plasmid containing the kidney androgen-regulated promoter, which is responsive to testosterone stimulation, was obtained from Dr. Curt D. Sigmund (University of Iowa, Iowa City, IA) and has been described elsewhere. 37, 38 A rabbit polyclonal antibody against rAgt was generated in our lab (J.S.D.C.). 39 Anti-Bax and anti-active caspase-3 polyclonal antibody were procured from New England Biolabs Ltd. (C) Caspase-3 activity. The graphs represent the mean Ϯ SD of four independent experiments and each treatment group was assayed in duplicate (*P Ͻ 0.05, **P Ͻ 0.01). pRC/RSV stable transfectants (empty bars) and pRSV/rAgt stable transfectants (solid bars).
Agt Tg Mice
We created Tg mice (C57Bl6 background, line #388) by inserting rAgt cDNA fused with an HA tag (a sequence encoding amino acid residues 98 to 106 (YPYDVPDYA) of human influenza virus hemagglutinin) at the 3Ј terminal into a construct containing the kidney androgenregulated promoter. 25 All animals received standard mouse chow and water ad libitum. The experimental procedures were approved by the Animal Protection Committee of the Centre Hospitalier de l'Université de Montréal (CHUM).
Physiologic Studies
Male Tg mice and non-Tg littermates were divided into four groups (eight mice per group). Group 1 (control group) received vehicle intraperitoneally. Group 2: Streptozotocin (STZ)-induced diabetes: The animals were administered STZ (50 mg/kg in 10 mM sodium citrate buffer, pH 4.5), intraperitoneally, daily for 5 consecutive days. Forty-eight hours after the last STZ administration, blood glucose level was determined with a Side-Kick Glucose Analyzer (Model 1500; Interscience, ON, Canada). Mice with blood glucose Ͼ16.6 mM were studied. Systolic BP was monitored with a BP-2000 tail-cuff pressure device (Visitech Systems, Apex, NC) 25 in the morning, at least 3 to 4 times a week for 10 wk after habituating mice to this procedure for at least 30 to 60 min per day for 5 d before the first BP reading. Each point represents the means Ϯ SD of three to four determinations per week per group of animals.
Twenty-four hours before euthanasia with CO 2 at 4 wk post-STZ administration, the animals were housed individually in metabolic cages to collect urine samples later assayed for glucose and ketone levels (KetoDiastix; Bayer Inc., Healthcare Division, Toronto, ON, Canada), and albuminuria (ELISA; Albuwell and Creatinine Companion; Exocell, Inc., Philadelphia, PA). 25 Body weight and blood glucose were measured. Both kidneys were removed, decapsulated, and then weighed together. Left kidneys were processed for histology and the right kidneys were used for isolation of renal proximal tubule (RPT). 25, 40 Morphologic Studies Four to five sections per kidney (eight animals per group) were counterstained with hematoxylin and eosin 25 and analyzed by two investigators unaware of the treatments.
The mean glomerular volume on 30 random glomerular sections per mouse was determined by the method of Weibel 41 with the Motics Images Plus 2.0 image analysis software (Motic, Richmond, BC, Canada). RPTC volume and tubular luminal area were measured from 100 RPTC and 50 RPT per mouse, respectively, with the same software. Outer cortical RPT with similar cross-sectional views and clear nuclear structure were selected. The mean cell volume was estimated by the Nucleator method. 42 Terminal Transferase-Mediated Deoxyuridine Triphosphate Nick End-labeling (TUNEL) Assay and Immunohistochemical Staining
The percentage of apoptotic RPTC (TUNEL kit; Roche Diagnostics) was estimated semiquantitatively as described by Kumar et al. 21, 23 Immunohistochemical staining was performed by standard avidinbiotin-peroxidase complex method (ABC Staining System; Santa Cruz Biotechnologies, Santa Cruz, CA). 25 Western Blotting and Real-time Quantitative Polymerase Chain Reaction Assays for Gene Expression
Western blotting was performed as described. 25, 39 Bax and Bcl-xL mRNA expression in mRPTs was quantified by real-time quantitative polymerase chain reaction 43 using forward and reverse primers corresponding to Bax, 44 Bcl-xL, 45 and ␤-actin cDNA 46 (Table 1) .
Cell Culture and Caspase-3 Activity Assay
Rat immortalized RPTC stably transfected with the control plasmid pRC/RSV or with a plasmid pRSV/rAgt containing the rAgt cDNA were cultured as described. 47 Caspase-3 activity was determined fluorimetrically (BD Bioscience Pharmingen, Mississauga, ON, Canada). 48 
Statistics
Data are expressed as mean Ϯ SD. The data are analyzed by one-way ANOVA and the Bonferroni test. P values Ͻ0.05 were considered significant.
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